諾唯贊(688105.SH):與諾泰生物簽訂戰略合作協議並擬設立合資公司
格隆匯6月6日丨諾唯贊(688105.SH)公佈,公司與江蘇諾泰澳賽諾生物製藥股份有限公司(簡稱“諾泰生物”)近日於南京市簽署《合成生物學合作項目戰略合作協議》,以合成生物學技術平臺爲基礎,結合有機合成、化學工藝等交叉技術,共同推進雙方在合成生物學領域的技術進步和項目合作。公司擬與諾泰生物共同設立一家生物製藥公司(簡稱“合資公司”或“項目公司”,具體名稱待定,以市場監督管理機關登記的最終名稱爲準),公司持股比例爲49%,諾泰生物持股比例爲51%,以此爲平臺開展後續合作與具體業務工作。合作項目的具體投資規模、建設方案等事項將由雙方另行約定並履行內部審議程序,尚具有不確定性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.